Page 96 - CIBEROBN2016-ENG

lEAD RESEARCHER
Tinahones Madueño, Francisco
Fund. Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) Hospital Universitario Carlos Haya
Plaza del Hospital Civil S/N 29000 Málaga
(+34) 951 034 016 [email protected] group Website
GROUP MEMBERS
Staff members: Coin Aranguez, Leticia | Fernández de Castro Ruz, Almudena | Morcillo Espina, Sonsoles | Oliva Olivera, Wilfredo | Picón César, Inmaculada Concepción | Vilches Pérez, Alberto Jesús
Associated members: Alcaide Torres, Juan | Barbarroja Puerto, Nuria | Bernal López, Ma Rosa | Cardona Díaz, Fernando | Castellano Castillo, Daniel | Clemente Postigo, Maria Mercedes | El Bekay, Rajaa | Fernández García, Diego | Fernández García, José Carlos | García Almeida, José Manuel | García Fuentes, Eduardo | Garrido Sánchez, Lourdes | Gómez Huelgas, Ricardo | López Siguero, Juan Pedro | Macías González, Manuel | Manchas Doblas, Isabel | Moreno Indias, Isabel | Queipo Ortuño, Ma Isabel | Roca Rodríguez, Ma del Mar
Main lines of research
• Obesity and related diseases. Our group is studying the relationship between obesity and its related metabolic diseases. We try to elucidate the mechanisms that protect some particular obese individuals who do not develop metabolic diseases or do it lately. Within these related diseases, we are focused on diabetes, postprandial lipidemia and cancer.
• Adipose tissue biology. Our group is studying the expansion capacity of the adipose tissue and its relationship with insulin resistance. Thus, we are studying the neogenic capacity of the mesenchymal cells from adipose tissue, the necrosis predisposition, autophagy and apoptosis as well as the pro-fibrotic capacity of the tissue, relating these factors to metabolic pathologies. Moreover, the group is studying lipogenic and angiogenic capacities of the different factors that modulate the expansion capacity of the adipose tissue and its relationship with the metabolic diseases.
• Study of the gut microbiota and related diseases. We are studying the bacterial profiles of the
gut microflora within different pathologic situations in order to establish its role in their origins and developments. Moreover, we are also studying the microbiota changes that interventions with polyphenols cause and the changes produced by the radiotherapy in oncologic patients.
96
PROGRAMMES
P3